Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma

被引：0
|
作者：
Hans C. Lee
Noopur S. Raje
Ola Landgren
Vijay V. Upreti
Jin Wang
Ariel A. Avilion
Xuguang Hu
Erik Rasmussen
Gataree Ngarmchamnanrith
Hisaki Fujii
Andrew Spencer
机构：
[1] The University of Texas MD Anderson Cancer Center,Department of Lymphoma/Myeloma
[2] Harvard Medical School,Center for Multiple Myeloma, Massachusetts General Hospital
[3] Memorial Sloan Kettering Cancer Center,Myeloma Service, Department of Medicine
[4] Amgen Inc.,Clinical Pharmacology Modeling & Simulation
[5] Amgen Inc.,Bioanalytical Sciences
[6] Amgen Inc.,Clinical Biomarkers & Diagnostics
[7] Amgen Inc.,Global Biostatistical Science
[8] Amgen Inc.,Clinical Development
[9] Amgen Inc.,Translational Medicine
[10] Monash University,Malignant Haematology & Stem Cell Transplantation Service, The Alfred Hospital
来源：
Leukemia | 2021年 / 35卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：255 / 258
页数：3
相关论文
共 50 条
  • [21] A First in Human Study Planned to Evaluate Hdp-101, an Anti-BCMA Amanitin Antibody-Drug Conjugate with a New Payload and a New Mode of Action, in Multiple Myeloma
    Strassz, Andras
    Raab, Marc S.
    Orlowski, Robert Z.
    Kulke, Michael
    Schiedner, Gudrun
    Pahl, Andreas
    BLOOD, 2020, 136
  • [22] T cells carrying an anti-BCMA bb2121 chemical receptor in patients with refractory and/or relapsed multiple myeloma
    Sammut, Rinzine
    Richez, Valentine
    HEMATOLOGIE, 2019, 25 (03): : 134 - 134
  • [23] Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function
    He, Shao-long
    Cheng, Yu-hang
    Wang, Di
    Xu, Meng-lei
    Que, Yi-mei
    Xu, Yan-jie
    Ma, Liang-ming
    Li, Chun-rui
    Zhou, Jian-feng
    CURRENT MEDICAL SCIENCE, 2021, 41 (03) : 474 - 481
  • [24] Beyond BCMA: Outcomes of relapsed/refractory multiple myeloma after progression on anti-BCMA T cell redirecting therapy.
    Arora, Sankalp
    Giri, Smith
    Godby, Kelly Nicole
    Ravi, Gayathri
    Costa, Luciano J.
    Bal, Susan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Increased Bone Turnover and Decreased BCMA Levels in Patients with Response to Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma
    Ussmann, Jule
    Fischer, Luise
    Born, Patrick
    Grieb, Nora
    Hoffmann, Sandra
    Baber, Ronny
    Wang, Song-Yau
    Kloetzer, Christina
    Heyn, Simone
    Herling, Marco
    Herling, Carmen
    Jentzsch, Madlen
    Franke, Georg-Nikolaus
    Hofbauer, Lorenz
    Platzbecker, Uwe
    Vucinic, Vladan
    Weidner, Heike
    Merz, Maximilian
    BLOOD, 2023, 142
  • [26] Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function
    Shao-long He
    Yu-hang Cheng
    Di Wang
    Meng-lei Xu
    Yi-mei Que
    Yan-jie Xu
    Liang-ming Ma
    Chun-rui Li
    Jian-feng Zhou
    Current Medical Science, 2021, 41 : 474 - 481
  • [27] PHASE I, OPEN-LABEL TRIAL OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Zhang, W.
    Zhao, W.
    Liu, J.
    He, A.
    Chen, Y.
    Cao, X.
    Yang, N.
    Wang, B.
    Zhang, P.
    Zhang, Y.
    Wang, F.
    Lei, B.
    Gu, L.
    Yang, Y.
    Bai, J.
    Zhang, R.
    Wang, X.
    Ma, X.
    Wang, J.
    Wang, J.
    Wei, L.
    Zhang, J.
    Zang, X.
    Zhuang, Q.
    Fan, F. X.
    HAEMATOLOGICA, 2017, 102 : 2 - 3
  • [28] A phase 1 multicenter study evaluating KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.
    Cornell, Robert F.
    Locke, Frederick Lundry
    Bishop, Michael Russell
    Orlowski, Robert Z.
    Larson, Sarah Marie
    Borrello, Ivan
    Giralt, Sergio
    Kumar, Shaji
    Nooka, Ajay K.
    Raje, Noopur S.
    Rossi, John M.
    Thomrongsith, Lisa
    Xue, Allen
    Roberts, Zachary
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
    Wang, Qingming
    Wei, Runhong
    Guo, Shufang
    Min, Chao
    Zhong, Xiong
    Huang, Hui
    Cheng, Zhi
    CANCER GENE THERAPY, 2024, 31 (01) : 108 - 118
  • [30] Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
    Mailankody, Sham
    Matous, Jeffrey, V
    Liedtke, Michaela
    Sidana, Surbhi
    Oluwole, Olalekan O.
    Mohan, Meera
    Cruz, Jose C.
    Nath, Rajneesh
    Anwer, Faiz
    Rossi, Adriana
    Htut, Myo
    Malik, Shahbaz A.
    Ghatta, Srinivas
    Dillon, Myles
    Ying, Wendy
    Navale, Lynn
    Karski, Erin E.
    Balakumaran, Arun
    Kumar, Shaji K.
    BLOOD, 2022, 140 : 4620 - 4622
12345